{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:33:09Z","timestamp":1793295189375,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100007334","name":"Ministry of Health and Family Welfare","doi-asserted-by":"publisher","award":["(N1760\/017\/RS)"],"award-info":[{"award-number":["(N1760\/017\/RS)"]}],"id":[{"id":"10.13039\/501100007334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Pediatr"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s12098-024-05135-9","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T23:54:29Z","timestamp":1716854069000},"page":"815-822","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacokinetic-Pharmacodynamic (PK-PD) Analysis of Second-Line Anti-Tubercular Drugs in Indian Children with Multi-Drug Resistance"],"prefix":"10.1007","volume":"92","author":[{"given":"Aparna","family":"Mukherjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshminarayanan","family":"Gowtham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushil Kumar","family":"Kabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Lodha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thirumurthy","family":"Velpandian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,28]]},"reference":[{"key":"5135_CR1","unstructured":"World Health Organization. Global Tuberculosis Report, 2020. Geneva, Switzerland: WHO; 2020. Available at: https:\/\/www.who.int\/publications\/i\/item\/9789240013131. Accessed on 14 Oct 2020."},{"key":"5135_CR2","unstructured":"Harausz EP, Garcia-Prats AJ, Law S, et al; Collaborative Group for Meta-Analysis of Paediatric Individual Patient Data in MDR-TB. Treatment and outcomes in children with multidrug-resistant tuberculosis: a systematic review and individual patient data meta-analysis. PLoS Med. 2018;15:e1002591."},{"key":"5135_CR3","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1080\/14656566.2017.1373090","volume":"18","author":"A Mukherjee","year":"2017","unstructured":"Mukherjee A, Lodha R, Kabra SK. Current therapies for the treatment of multidrug-resistant tuberculosis in children in India. Expert Opin Pharmacother. 2017;18:1595\u2013606.","journal-title":"Expert Opin Pharmacother"},{"key":"5135_CR4","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1124\/jpet.103.060137","volume":"308","author":"SB Koukouritaki","year":"2004","unstructured":"Koukouritaki SB, Manro JR, Marsh SA, et al. Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther. 2004;308:965\u201374.","journal-title":"J Pharmacol Exp Ther"},{"key":"5135_CR5","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1124\/jpet.300.2.361","volume":"300","author":"DG McCarver","year":"2002","unstructured":"McCarver DG, Hines RN. The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J Pharmacol Exp Ther. 2002;300:361\u20136.","journal-title":"J Pharmacol Exp Ther"},{"key":"5135_CR6","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S1359-6446(05)03620-2","volume":"10","author":"WA Korfmacher","year":"2005","unstructured":"Korfmacher WA. Principles and applications of LC-MS in new drug discovery. Drug Discov Today. 2005;10:1357\u201367.","journal-title":"Drug Discov Today"},{"key":"5135_CR7","unstructured":"Migliori GB, Tiberi S, Zumla A, et al; Members of the Global Tuberculosis Network. MDR\/XDR-TB management of patients and contacts: challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. Int J Infect Dis. 2020;92S:S15\u201325."},{"key":"5135_CR8","doi-asserted-by":"publisher","first-page":"e01521","DOI":"10.1128\/AAC.01521-17","volume":"62","author":"P Denti","year":"2018","unstructured":"Denti P, Garcia-Prats AJ, Draper HR, et al. Levofloxacin population pharmacokinetics in South African children treated for multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2018;62:e01521\u201317.","journal-title":"Antimicrob Agents Chemother"},{"key":"5135_CR9","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.1128\/AAC.02755-13","volume":"58","author":"S Thee","year":"2014","unstructured":"Thee S, Garcia-Prats A, McIlleron H, et al. Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children. Antimicrob Agents Chemother. 2014;58:2948\u201351.","journal-title":"Antimicrob Agents Chemother"},{"key":"5135_CR10","doi-asserted-by":"publisher","first-page":"4594","DOI":"10.1128\/AAC.00379-11","volume":"55","author":"S Thee","year":"2011","unstructured":"Thee S, Seifart H, Rosenkranz B, et al. Pharmacokinetics of ethionamide in children. Antimicrob Agents Chemother. 2011;55:4594\u2013600.","journal-title":"Antimicrob Agents Chemother"},{"key":"5135_CR11","doi-asserted-by":"publisher","first-page":"e02410","DOI":"10.1128\/AAC.02410-17","volume":"62","author":"AK Hemanth Kumar","year":"2018","unstructured":"Hemanth Kumar AK, Kumar A, Kannan T, et al. Pharmacokinetics of second-line antituberculosis drugs in children with multidrug-resistant tuberculosis in India. Antimicrob Agents Chemother. 2018;62:e02410\u201317.","journal-title":"Antimicrob Agents Chemother"},{"key":"5135_CR12","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s13312-013-0085-1","volume":"50","author":"A Kumar","year":"2013","unstructured":"Kumar A, Gupta D, Nagaraja SB, Singh V, Sethi G, Prasad J. Updated national guidelines for pediatric tuberculosis in India, 2012. Indian Pediatr. 2013;50:301\u20136.","journal-title":"Indian Pediatr"},{"key":"5135_CR13","unstructured":"Kuczmarski RJ, Ogden CL, Guo SS, et al. 2000 CDC growth charts for the United States: Methods and development. National Center for Health Statistics. Vital Health Stat. 2002;11. Available at: https:\/\/www.cdc.gov\/nchs\/data\/series\/sr_11\/sr11_246.pdf. Accessed on 30 June 2010."},{"key":"5135_CR14","unstructured":"FDA Guidance for Industry, Bioanalytical method validation. 2018. Available at: https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf . Accessed on 24 May 2018."},{"key":"5135_CR15","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","volume":"99","author":"Y Zhang","year":"2010","unstructured":"Zhang Y, Huo M, Zhou J, Xie S. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed. 2010;99:306\u201314.","journal-title":"Comput Methods Programs Biomed"},{"key":"5135_CR16","doi-asserted-by":"publisher","first-page":"S317","DOI":"10.1093\/cid\/ciy609","volume":"67","author":"D Deshpande","year":"2018","unstructured":"Deshpande D, Pasipanodya JG, Mpagama SG, et al. Ethionamide pharmacokinetics\/pharmacodynamics-derived dose, the role of MICs in clinical outcome, and the resistance arrow of time in multidrug-resistant tuberculosis. Clin Infect Dis. 2018;67:S317\u201326.","journal-title":"Clin Infect Dis"},{"key":"5135_CR17","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1128\/AAC.01478-13","volume":"58","author":"SP Zvada","year":"2014","unstructured":"Zvada SP, Denti P, Sirgel FA, et al. Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients. Antimicrob Agents Chemother. 2014;58:503\u201310.","journal-title":"Antimicrob Agents Chemother"},{"key":"5135_CR18","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1093\/jac\/dkw164","volume":"71","author":"S Ghimire","year":"2016","unstructured":"Ghimire S, Van\u2019t Boveneind-Vrubleuskaya N, Akkerman OW, et al. Pharmacokinetic\/pharmacodynamics based optimization of levofloxacin administration in the treatment of MDR-TB. J Antimicrob Chemother. 2016;71:2691\u2013703.","journal-title":"J Antimicrob Chemother"},{"key":"5135_CR19","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1592\/phco.21.11.891.34524","volume":"21","author":"M Zhu","year":"2001","unstructured":"Zhu M, Nix DE, Adam RD, Childs JM, Peloquin CA. Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids. Pharmacotherapy. 2001;21:891\u20137.","journal-title":"Pharmacotherapy"},{"key":"5135_CR20","doi-asserted-by":"publisher","first-page":"e01724","DOI":"10.1128\/AAC.01724-17","volume":"62","author":"J Dijkstra","year":"2018","unstructured":"Dijkstra J, van der Laan T, Akkerman O, et al. In vitro susceptibility of Mycobacterium tuberculosis to amikacin, kanamycin, and capreomycin. Antimicrob Agents Chemother. 2018;62:e01724\u201317.","journal-title":"Antimicrob Agents Chemother"},{"key":"5135_CR21","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1093\/jac\/dkx506","volume":"73","author":"N Dookie","year":"2018","unstructured":"Dookie N, Rambaran S, Padayatchi N, Mahomed S, Naidoo K. Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care. J Antimicrob Chemother. 2018;73:1138\u201351.","journal-title":"J Antimicrob Chemother"},{"key":"5135_CR22","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.2165\/00003495-200262150-00001","volume":"62","author":"CA Peloquin","year":"2002","unstructured":"Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs. 2002;62:2169\u201383.","journal-title":"Drugs"},{"key":"5135_CR23","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1007\/s12098-019-02923-6","volume":"86","author":"G Ramachandran","year":"2019","unstructured":"Ramachandran G. Pharmacokinetics of second-line anti-tubercular drugs. Indian J Pediatr. 2019;86:714\u20136.","journal-title":"Indian J Pediatr"},{"key":"5135_CR24","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1002\/psp4.12697","volume":"10","author":"P Vaddady","year":"2021","unstructured":"Vaddady P, Kandala B. ModVizPop: a shiny interface for empowering teams to perform interactive pharmacokinetic\/pharmacodynamic simulations. CPT Pharmacometrics Syst Pharmacol. 2021;10:1323\u201331.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"5135_CR25","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S0969-8043(97)00076-6","volume":"49","author":"C M\u00f8lgaard","year":"1998","unstructured":"M\u00f8lgaard C, Michaelsen KF. Changes in body composition during growth in healthy school-age children. Appl Radiat Isot. 1998;49:577\u20139.","journal-title":"Appl Radiat Isot"},{"key":"5135_CR26","doi-asserted-by":"crossref","first-page":"e00343","DOI":"10.1128\/AAC.00343-17","volume":"61","author":"N Van't Boveneind-Vrubleuskaya","year":"2017","unstructured":"Van\u2019t Boveneind-Vrubleuskaya N, Seuruk T, van Hateren K, et al. Pharmacokinetics of levofloxacin in multidrug-and extensively drug-resistant tuberculosis patients. Antimicrob Agents Chemother. 2017;61:e00343\u201317.","journal-title":"Antimicrob Agents Chemother"},{"key":"5135_CR27","doi-asserted-by":"publisher","first-page":"1701778","DOI":"10.1183\/13993003.01778-2017","volume":"51","author":"SK Heysell","year":"2018","unstructured":"Heysell SK, Ahmed S, Rahman MT, et al. Hearing loss with kanamycin treatment for multidrug-resistant tuberculosis in Bangladesh. Eur Respir J. 2018;51:1701778.","journal-title":"Eur Respir J"},{"key":"5135_CR28","doi-asserted-by":"publisher","first-page":"S308","DOI":"10.1093\/cid\/ciy624","volume":"67","author":"D Deshpande","year":"2018","unstructured":"Deshpande D, Alffenaar JWC, K\u00f6ser CU, et al. d-Cycloserine pharmacokinetics\/pharmacodynamics, susceptibility, and dosing implications in multidrug-resistant tuberculosis: a Faustian deal. Clin Infect Dis. 2018;67:S308\u201316.","journal-title":"Clin Infect Dis"},{"key":"5135_CR29","doi-asserted-by":"publisher","first-page":"e00055","DOI":"10.1128\/AAC.00055-19","volume":"63","author":"WA Alghamdi","year":"2019","unstructured":"Alghamdi WA, Alsultan A, Al-Shaer MH, et al. Cycloserine population pharmacokinetics and pharmacodynamics in patients with tuberculosis. Antimicrob Agents Chemother. 2019;63:e00055\u201319.","journal-title":"Antimicrob Agents Chemother"},{"key":"5135_CR30","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1164\/ajrccm.159.3.9807131","volume":"159","author":"CA Peloquin","year":"1999","unstructured":"Peloquin CA, Berning SE, Huitt GA, Childs JM, Singleton MD, James GT. Once-daily and twice-daily dosing of p-aminosalicylic acid granules. Am J Respir Crit Care Med. 1999;159:932\u20134.","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Indian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12098-024-05135-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12098-024-05135-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12098-024-05135-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T19:54:30Z","timestamp":1757102070000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12098-024-05135-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,28]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["5135"],"URL":"https:\/\/doi.org\/10.1007\/s12098-024-05135-9","relation":{},"ISSN":["0019-5456","0973-7693"],"issn-type":[{"value":"0019-5456","type":"print"},{"value":"0973-7693","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,28]]},"assertion":[{"value":"22 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}